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Abstract
Extracellular vesicles (EVs) are known to perform important biological functions and have been implicated in multiple disease 
pathogeneses, including HIV and drugs of abuse. EVs can carry biological molecules via biofluids such as plasma and cerebro-
spinal fluids (CSF) from healthy or disease organs to distant organs and deliver biomolecules to recipient cells that subsequently 
alter the physiology of the recipient organs. As biocarriers, EVs have the potential to be developed as non-invasive biomarkers for 
disease pathogenesis and drug abuse, as the level of specific EV components can be altered under disease/drug abuse conditions. 
Since many drugs don’t cross the blood-brain barrier, EVs have shown the potential to encapsulate small drug molecules, 
including nucleotides, and carry these drugs to brain cells and enhance brain drug bioavailability. Through this special issue, 
we have covered several studies related to the role of EVs in altering biological functions via cell-cell interactions in healthy, 
HIV, and drug of abuse conditions. We have also included studies on the role of EVs as potential biomarkers for HIV patho-
genesis and drugs of abuse. Further, the potential role of EVs in drug delivery in the CNS for diseases, including HIV-associated 
neurocognitive disorders and other neurological disorders, are covered in this issue.
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Extracellular vesicles (EVs), especially exosomes, are
nanovesicles that have been recognized as valuable targets
for biological research. Although EVs were first isolated and
characterized in the late 1980s, their potential in biological
research was not realized until a decade ago. EVs are pro-
duced by most cell types and are secreted into biofluids such
as plasma, cerebrospinal fluids (CSF), and saliva, and trans-
port their molecular cargos between diverse cell types at dis-
tant organs via these fluids. These qualities make them key
mediators in intercellular communication both in healthy, dis-
ease, and other conditions, e.g. drug abuse. Based on the trig-
gers and physiological conditions of the cells/organs, EVs
may carry toxic or protective components, which upon deliv-
ering to the recipient cells/organs, may cause cytotoxicity/
organ damage or cellular/organ protection, respectively.
The semi-selective ability to package and transport diverse
biological cargos such as proteins, miRNAs, lipids, and small
molecules, allow EVs to serve as diagnostic biomarkers of
disease states and other conditions. Due to their relative sta-
bility, availability in biofluids, and stimulus-inducible cargos,
EVs are ideal candidates for biomarkers of many diseases,
including HIV and drugs of abuse conditions. In addition,
due to their natural ability to transport biomolecules, EVs have
been studied for potential drug delivery systems for therapeu-
tic interventions. This special issue features several papers that
highlight the role of EVs in drug delivery modalities, espe-
cially across the blood-brain barrier (BBB), for the interven-
tions of many CNS diseases, including HIV and HIV-
Associated Neurocognitive Disorder (HAND).
Although, over the years, multiple EV isolation and purifi-
cation methods have been developed, it is very difficult to
separate EVs from viruses due to the similar sizes. Thus, it
is imperative to separate these two populations to avoid mis-
interpretations of data. Here, McNamara and Dittmer de-
scribed modern methods that combine ultracentrifugation,
cross flow filtration, column chromatography, including affin-
ity chromatography, as well as NanoFACS and Flow
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Virometry (McNamara and Dittmer 2019). Depending upon
the contaminant viruses, such as human immunodeficiency
virus (HIV), hepatitis A, or influenza, as described in the pa-
per, a combination of these methods can be used. International
Society of Extracellular Vesicles (ISEV) 2018 guidelines rec-
ommend optimal use of isolation method(s) based on the
source and application of EVs. Thus, different methods or a
combination of methods can be used in different studies de-
pending upon the source or outcome measures of the EVs in
that study.
EVs transported from peripheral or stem cells via plasma can
infiltrate into the CNS and deliver their components to the brain
cells causing physiological changes. In a study presented here,
Branscome et al. have shown that induced pluripotent stem cell-
(iPSC) and mesenchymal stem cell- (MSC) derived EVs dis-
play immunomodulatory properties with distinct mechanisms
in CNS cells (Branscome et al. 2019). They have shown the
potential of these EVs in repairing damaged cells. The study has
implications with regard to the role of iPSC- and MSC-derived
EVs in therapeutic interventions for CNS diseases in which
brain cells are damaged as a result of stimuli.
Both HIV and drug abuse stimulate specific cell types/
organs to secrete EVs containing specific components. As
reviewed by Rahman et al., alcohol exposure modifies the
contents of hepatic and extra-hepatic EVs, which translocate
via plasma, and deliver their cargos to non-hepatic cells and
alter inflammatory responses (Rahman et al. 2019). Some of
the components that are elevated upon alcohol exposures are
the alcohol-metabolizing cytochrome P4502E1 enzyme, anti-
oxidant enzymes, oxidative stress-inducing miRNAs, and cy-
tokines and chemokines. However, the underlyingmechanism
of packaging of these components and their specific roles in
recipient cells are poorly known. Thus, a complete under-
standing of the interplay between EVs and alcohol is neces-
sary to develop EVs as biomarkers for alcohol or other drug-
induced pathogeneses. In a study by Wang et al., the dysreg-
ulation of plasma exosomal miRNAs by HIV infection and/or
heroin use, was demonstrated (Wang et al. 2019). However,
the source of EVs containing these miRNAs is still under
investigation. Thus, in addition to investigating the source of
these plasma EVs, it is imperative to study whether dysregu-
lated EV miRNAs play a role in HIV and/or heroin use-
mediated immune dysfunction and neurotoxicity. In a separate
study, Hu et al. demonstrated the role of the HIV-1 protein Tat
in induction and release of EV miRNA-7 from astrocytes (Hu
et al. 2019). The EV miRNA-7 is taken up by neurons and
downregulates neuronal neuroligin 2 (NLGN2), ultimately al-
tering synaptic functions. This is another important finding
with respect to the role of HIV in inducing EV cargos that
alter disease physiology by cell-cell interactions.
Autophagy-exosome interplay, which is generally triggered
by oxidative stress, causes both survival and cell death based on
the intensity/dose or exposure time of a stimuli. Here,
Olanrewaju and Hakami reviewed the implications of
autophagy-exosome interplay for microglial response to HIV
infection within the CNS (Olanrewaju and Hakami 2020).
They report the involvement of specific protein complexes that
contain autophagy-related (ATG) proteins, such as ATG101,
ATG13, FIP200, in exosome packaging during infection, or
the influence of exosome-associated tetraspanins, e.g. CD63
and CD81, on autophagy response during infection. ATG101,
ATG13 and FIP200 are also involved in the phagophore forma-
tion and elongation processes, which are essential in the autoph-
agy pathway. The current investigation of exosome-autophagy
crosstalk in microglia in the PD system is important, as
microglial function is also implicated in HIV and neuroAIDS.
EVs and their specific components, obtained from
biofluids such as plasma, urine, and saliva, are considered
important non-invasive diagnostic markers for cancers and
other diseases/conditions. In one of the studies presented here,
Kodidela et al. identified specific plasma EV proteins that
were altered in HIV + individuals, however, different proteins
were altered in HIV-infected drinkers or smokers (Kodidela
et al. 2019). For example, hemopexin was not altered in
drinkers or HIV + individuals, but was altered in HIV +
drinkers. Additionally, properdin was not altered in HIV + or
smoker groups, but was altered in HIV + smokers. These re-
sults suggest an important role for hemopexin and properdin
in HIV-alcohol and HIV-tobacco interactions, respectively.
Since drug abuse is known to exacerbate HIV pathogenesis
and HAND, it is of great significance to develop diagnostic
markers for HAND in HIV populations who also abuse drugs
such as alcohol, tobacco, cocaine, and opioids.
Due to the small size and lipophilic nature of EVs, they are
increasingly being exploited as delivery vehicles of therapeu-
tics for anticancer strategies, immunomodulation, targeted
drug delivery, tissue regeneration, and vaccination. In the re-
view by Sil et al., they highlight the pros and cons of using
EVs as conduits of proteins, lipids, carbohydrates, mRNAs,
long non-coding RNAs, microRNAs and DNAs for therapeu-
tic agents (Sil et al. 2019). Efficient targeted delivery of anti-
cancer agents to cancer cells remains one of the greatest chal-
lenges to developing therapies. In the article by Haney et al.,
they exploit the natural ability of macrophages to target cancer
cells by means of EVs as drug delivery vehicles for the che-
motherapeutic agents, paclitaxel (PTX) and doxorubicin
(Dox) (Haney et al. 2019). Using a mouse model of pulmo-
nary metastases, they demonstrated that macrophage-derived
EVs loaded with PTX (EV-PTX) and Dox (EV-Dox) target
cancer cells and exhibit high anticancer efficacy. As a nice
follow-up, in the review article by Shahjin et al., they
discussed the challenges faced in EV research as it relates to
HIV-1 co-morbid conditions and the potential of nanotechnol-
ogies, especially EVs, in Neuro-AIDS (Shahjin et al. 2019).
The structure of the BBB, the presence of efflux pumps, and
the expression of metabolic enzymes, pose hurdles for drug-
brain entry. With only a limited number of drugs, including
small lipophilic compounds, transmigrating the BBB, drug
delivery to the CNS has become a challenge and much effort
has been invested into improving the route of drugs to the
brain. In the article by Reynolds and Mahajan, they tackled
another important issue related to the development of target-
specific therapy in the brain (Reynolds and Mahajan 2019).
They used an artificial BBB model system to investigate the
transmigration of microglia-derived exosomes containing
siRNA targeting Tetraspanin (Tspan)-2, expressed on microg-
lia cells. Successful transmigration of the exosomes across the
BBB was evaluated by the knockdown of Tspan2 and by the
modulation of neuroimmune responses in HIV-infected
microglial cells plated on the basal side of the BBB. In the
article by Liao et al., they bypassed the BBB and intranasally
delivered EVs loaded with Long non-coding RNAs
(lncRNAs) in the brains of mice (Liao et al. 2019).
Intranasal delivery is a non-invasive method to deliver drugs
to the brain that has been proven safe and effective.
As described in this issue, the understanding of the role of
EVs as natural carriers of biomolecules and the use of EVs as
drug delivery vehicles offers a number of benefits over com-
mon drug administration regimens. However, limitations and
challenges still exist that need to be addressed in future re-
search to improve the development of drug delivery strategies
aided in saving lives.
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